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Migraine is a serious episodic headaches affecting more than 15% of the human population with 
a detrimental influence on the patients’ life and socioeconomic functioning. Although many 
pathophysiological and molecular mechanisms of migraine have been suggested, little is known 
about the molecular disruption in a chronic migraine. Here, we propose to characterize the 
differences of the gene expression, biological processes and pathways, and regulatory network 
between individuals with control and a hyperalgesia mouse model of chronic migraine. Chronic 
hyperalgesia was modeled using a nitroglycerin treatment. The transcriptome was characterized 
in the trigeminal ganglia and nucleus accumbens. Samples were sequenced using the Illumina 
HiSeq 4000 platform to produce paired end reads of 100 bp. Opalin, Slc32a, Cacna1b, and H2-
Eb2 were among the 110 genes exhibiting significant interaction effects. The 165 genes 
presenting different expression patterns between the treatment and control groups included 
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CHAPTER 1. LITERATURE REVIEW 
 
Migraine 
 Migraine is a disorder that is characterized by serious episodic headaches that affect 
approximately more than 15% of the human population with a significant detrimental influence 
on the patients’ life [1]. More than 20% of patients suffer from extreme pain, and more than 3% 
of migraine patients develop into chronic migraine cases each year [2]. Also, migraine has a 
severe impact on the patient’s socioeconomic functioning in addition to the quality of life. 
 Migraine is a typical primary headache disorder characterized by recurrent, paroxysmal 
headaches accompanied by edema, vomiting, and local neurological symptoms. The incidence 
and severity of these headaches vary from patient to patient [3]. A headache is classified into 
primary and secondary headaches [4]. Primary headache is not a headache caused by other 
diseases or problems, but pain itself is a disease. Secondary headache, on the other hand, is a 
headache caused by other diseases such as infection or tumors. More than 90% of a total 
headache is included in primary headache, and migraine is the most common type of primary 
headache. Also, more than 37% of all patients in the United States who have headaches are 
classified as migraineurs [5]. About 8% of patients with migraine suffer from chronic migraine 
[2]. In general, primary migraine is very rare. Instead, chronic migraine usually evolves slowly 
from acute migraine with increased frequency of pain. Interestingly, many studies suggested that 
gender and educational status were associated with chronicity of migraine [2, 6, 7]. 
 Although the medical cause of migraine is not been clearly identified, it is presumed that 
various environmental factors and genetic factors play a major role. Several risk factors are 
known to increases the risk of migraine. Migraine is reported to occur three times more often in 
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women than in men [5, 8]. In women, migraine has the highest peak in the mid-20s and the 
second highest in the mid-40s [2]. Also, migraine is considered to have a strong genetic 
component with a polygenic inheritance. One study with 464 migraine patients identified that 
approximately 55% had a family history of migraine [9]. Recent genome-wise association 
studies identified several migraine susceptibility genetic loci including genes encoding ion 
channels and synaptic transmission [10-12]. Several mutations in calcium channel-related genes 
were responsible for familial hemiplegic migraine, which is a type of migraine accompanied 
speech difficulties or vision problems that run in families [13, 14].  
 
Pathophysiology of migraine 
 Since migraine is characterized by a variety of clinical features and triggering factors, 
many theories about the pathophysiology and molecular mechanisms of migraine have been 
suggested. In particular, there has been a debate about whether migraine is a disease caused by a 
vascular disorder or neuronal dysfunction [15-17]. Most current acute migraine medications 
constrict cerebral blood vessels based on the hypothesis that migraine is a vascular disease [18-
20]. In particular, a meta-analysis of 22 genome-wide association studies based on the 375,000 
migraine patients identified several significant loci were associated with vascular diseases and 
smooth muscle contraction, which supports the vascular disorder hypothesis [21]. However, the 
absence of associations between vascular anomalies and migraine refutes the existing vascular 
disorder hypothesis. A study showed that there was no significant effect of the vasoactive 
intestinal polypeptide on migraine [22]. Also, Bosentan, an antagonist of endothelin receptor, can 
abort the symptoms of migraine with no vasoconstrictor activity [23, 24].  
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 Recent migraine studies have focused on the theory that the pathophysiology of migraine 
is related to neurovascular disorder assuming neurological disorders from the meningeal blood 
vessels cause the cephalic pain [25, 26]. The sensitivity of headache is mainly limited to the 
meningeal blood vessels, which are innervated by nociceptive sensory afferent fibers of the first 
branch of the trigeminal nerve [27]. Also, it is assumed that the activation of meningeal 
trigeminovascular afferents might be related to the development of migraine headache [28, 29]. 
The activation of the trigeminal ganglion stimulates the release of neuropeptides such as 
calcitonin gene-related peptide (CGRP), substance-P, and neurokinin A, which play a causal role 
in a neurogenic inflammation of the meningeal blood vessels wall [30, 31]. 
 
Nitroglycerine model of migraine 
 One of the significant obstacles to study migraine was a lack of predictive animal models 
for experiment. To solve this problem, chemical substances that cause traits similar to migraine 
headaches have been identified. For example, nitroglycerin (NTG), a lipophilic substance that 
can easily cross the barrier between the brain and blood barrier, makes it possible to monitor the 
progression of migraine-like headaches by controlling a dose, opening new possibilities for 
migraine treatment [32, 33]. The NTG injection releases nitric oxide (NO) which is established 
that not only did it involve immediate headache due to the vasodilation effect, but also affects the 
nerve function potentially leading to chronic headache [34]. The injection also triggers 
sensitivity to sensory stimuli, which is a common symptom in migraine patients [35]. The 
administration of NTG has been commonly used as a model to trigger migraine in human 
studies. A study of hyperalgesia resembling migraine sampled from nine patients induced by oral 
administration of NTG was performed to clarify the mechanisms occurring during acute 
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migraine [36]. Also, a study of 17 migraine patients showed that dose-dependent headaches with 
increased pain as the increase of the dose of NTG was identified in all groups [37].  
 Nitroglycerin treatment is also used in predictive animal models. The injection of NTG 
results in sensory hypersensitivity associated with migraine in rodent, and it triggers a light-
aversive behavior which is associated with a symptom of migraine [38]. This induces C-fos 
expression in the trigeminal nucleus caudalis mediated by the neurotransmitters from the central 
terminal [39]. A RNA-Seq study of the trigeminal ganglia in a rodent model showed the 
possibility that NTG-evoked migraine-like symptoms in rodents can be used to identify the genes 
associated with migraine [40]. However, the understanding of migraine is still incomplete. In 
order to clarify the molecular mechanism of migraine headache, it is necessary to use a chronic 
migraine model by intermittent administration of NTG. In addition, experiments using various 
brain regions will be required for the identification of molecular pathways that occur specifically 
between brain regions. 
 
Transcriptome analysis 
 Transcriptome represents a total amount of transcripts in a cell. This allows researchers to 
quantify the expression of genes under certain conditions. Also, the quantification of 
transcriptome can be applied to identify genes which have different expression patterns among 
certain conditions or tissue regions. Various transcriptome analysis techniques have been 
developed, and these techniques have enabled reducing the analysis cost and analyzing massive 
data as a high-throughput manner [41, 42]. 
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 The microarray technique using hybridization-based method has been the mainstream for 
the analysis of transcripts. However, this technique has several limitations which include: the 
pre-existing of genomic sequences for transcriptome analysis; the difficulty of precise 
quantitative comparison between different experiments due to the complexity of normalization. 
Also, it has relatively low accuracy in terms of quantification since it is not a sequence-based 
analysis method [43]. 
 Recent advances in technology, known as Next Generation Sequencing (NGS), have 
made it possible to analyze a massive amount of sequence-based genomic- and transcriptomic 
information. Unlike the conventional microarray method, RNA-Seq, which is RNA sequencing 
using NGS technique, has a variety of advantages by using actual sequence information for the 
downstream analysis [44]. First, accurate quantification of gene expression is possible. In 
contrast to the microarray, the expression of genes can be obtained in units of 'digit'. Also, 
approximate quantification is possible even without genomic information [45]. 
  In addition, RNA-Seq technology can be used to reveal differences in sequence 
information such as single nucleotide polymorphisms or alternative splicing events under 
specific conditions or tissue. Also, it can reveal various small RNAs (microRNA, piwi-
interacting RNA, small interfering RNA, and many others), which can regulate expression level 
of other genes [44]. 
 
Workflow to analyze RNA-Seq 
 A typical RNA-Seq workflow for analyzing differential expression starts with the 
construction of RNA-Seq library. mRNA is converted to cDNA through reverse transcription. It 
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is important to extract the high quality RNA to success of a RNA-Seq analysis. In addition, more 
than 100 ng of RNA is required to construct the RNA-Seq library [46]. Currently, the most 
widely used NGS platform is Illumina HiSeq, which yields more than 3 billion sequencing reads 
per each run. The Illumina HiSeq platform uses a technique called sequencing-by-synthesis 
producing paired-end reads ranging from 50bp to 150bp long [47]. The choice of read length can 
be determined depending on the sequencing depth or alternative splicing target. Also, it 
determined by the species being analyzed. Usually, a species with a relatively less repeat 
sequence will be accurately analyzed even with a short read of 50 bp, whereas species with 
highly repetitive genomes require longer reads to accurately analyze gene expression levels [48].    
 In order to quantify the accurate gene expression level, the quality of sequence reads 
should be evaluated using tools such as FastQC that summarizes sequencing quality in a base-
pair level [49]. Subsequently, a typical RNA-Seq analysis includes two steps: 1) mapping the 
sequenced reads to the genome or transcriptome, and 2) estimating the abundances of the 
transcripts. The first step, which is a read alignment step, is conducted to determine where each 
read originates from a reference genome or transcriptome. However, this step can be time 
consuming because it matches all the reads to the reference with a base level alignment. For 
example, it takes 28 cpu core hours to align 20 samples of each with 30 million RNA-Seq reads 
using the most widely used software program Tophat2 [50]. Moreover, additional 14 hours 
should be taken to quantify the abundance of transcripts using companion program Cufflinks 
[51].  
 Many analytical tools have been developed to reduce bottlenecks in such data analysis. 
The rationale of the new approach to reduce the analysis time is to find out which transcripts the 
reads are derived from, rather than the exact location of them in the transcripts. This method is 
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called alignment independent or pseudo-alignment, and it takes less than 10 minutes to analyze 
30 million RNA-seq reads with a standard personal computer using Kallisto [52], one of the most 
accurate and fastest software program. First, Kallisto builds the de Bruijn graph of the reference 
transcriptome which is constructed from the set of all the possible subsequences of length k (k-
mers) in the reference transcriptome. Subsequently, k-mers of each RNA-Seq read match to the 
corresponding k-mers in the graph, resulting in a fast and low memory usage approach [52]. 
Kallisto then quantifies expected read counts for each transcript based on the results from 
pseudo-alignment.  
 Following read alignment and quantification of expression levels, a next step is to 
identify genes or transcripts that exhibit differential expression between different conditions. To 
do so, the quantification data should be normalized to compare expression level from different 
conditions [48]. Two kinds of sequencing bias should be considered when performing 
normalization. The first is the bias that occurs within a sample due to the different length of 
transcripts, and the other is between-sample bias because of the differences in sequencing depth 
between samples.  
 The indicators reads per kilobase per million mapped reads (RPKM) or fragments per 
kilobase per million mapped reads (FPKM) has been widely used to adjust these biases by 
transforming raw count data to the adjusted counts based on the total gene length and mapped 
reads within a sample [45]. First, it simply counts up the total reads and divides it by a million to 
obtain a “per million” scaling factor. Next, read counts of each gene were divided by this scaling 
factor which refers to reads or fragments per million (RPM or FPM) to adjust different 
sequencing depth between samples. Lastly, the RPM or FPM is divided by the length of its 
corresponding gene to normalize it by gene length in kilobase (RPKM or FPKM). Although 
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RPKM and FPKM were popular normalization methods, the sum of all normalized read counts 
of them is different in all samples, the numerical value itself makes it difficult to make an 
accurate comparison between samples. TPM (transcripts per kilobase per million mapped reads) 
is now widely used and become a popular normalization strategy [53]. TPM is very similar to 
RPKM or FPKM but the only difference is the order of the steps. It first divides the read counts 
of each gene by its corresponding length of the gene and divides the sum of all the normalized 
values by a million to obtain the scaling factor. The normalized values are further divided by the 
scaling factor to obtain final normalized counts (TPM).  Unlike RPKM or FPKM, the sum of all 
TPM values in a sample is always constant at one million, and this makes it easier to compare 
the proportion of gene counts in each sample.  
 Various software programs such as EdgeR and DESeq can be used to test for the 
differential expression in gene or transcript level [54, 55]. The relative abundance of each gene 
between different conditions are modeled and tested. Unlike array-based data, which uses 
continuous intensity as a response variable, assuming the normal distribution for gene expression 
levels, both EdgeR and DESeq methods assume the negative binomial distribution since the 
expression level is expressed by the actual read count. Both methods use similar normalization 
factors and have interchangeable performance but differ in the approaches to the estimation of 
dispersion. The EdgeR method moderates the dispersion estimates based on the dispersion-mean 
relationship which is more sensitive to outliers, while the DESeq method maximizes the 
dispersion estimates which has less power than the EdgeR method. A list of differentially 




  It is possible to identify many gene candidates involved in a particular condition or tissue 
region by exploring the functional analysis of each gene among the genes that have differential 
expression. However, the list of differentially expressed genes obtained from RNA-Seq analysis 
contains hundreds of genes or transcripts. To derive meaningful biological functions from a list 
of many genes, it is necessary to explore the enrichment of functional categories and biological 
pathways by using the database that is designed based on the biological knowledge analysis [56]. 
The Database for Analysis, Validation, and Integrated Discovery (DAVID) integrates functional 
annotations including the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) with user-friendly graphical summaries [57]. In addition, DAVID can reduce 
similar redundant functional categories and analyze biologic interpretations focusing on group 
level by using the Functional Annotation Clustering analysis, which measure relationships of 
annotated terms based on the degrees of their co-association genes [58]. 
 In addition, the Gene Set Enrichment Analysis (GSEA) method can explore statistically 
significant enriched gene sets for interpreting gene expression data based on the ordered list of 
genes according to their statistical significances or expression fold changes [59]. Like DAVID 
analysis, it uses knowledge based approaches using published information in previous 
experiments. However, GSEA considers entire ranked list of genes providing comprehensive list 
of enriched gene sets which might be not detected from DAVID. 
 Also, using a differential expression gene list, it is possible to perform network analysis 
between transcription regulatory factors (TF) and target genes using software program such as 
iRegulon [60]. The iRegulon identifies genes that are co-regulated through motif discovery since 
TF target genes have a common TF binding site regulated as a cis-regulatory control. First, 
homotypic motif clusters are searched at 20kb around all transcription initiation sites of each 
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gene using Hidden Markov Model. A gene-ranking for each position weight matrices is 
constructed. Then, it identifies the enriched motif in the input gene and enrichment is measured 
as a normalized enrichment score. The candidate TFs are predicted based on the information of 
enriched motifs and the final output is represented by TF and its target genes. 
 
Objectives 
 Although several known molecular mechanisms have been characterized, the 
understanding of molecular mechanisms of chronic migraine is still incomplete. In an effort to 
understand the molecular disruption in a chronic migraine, we performed a comparative 
transcriptomic analysis of the trigeminal ganglia (TG) and nucleus accumbens (NAc) sampled 
from male rats at 30 and 90 min post NTG infusion using as a hyperalgesia mouse model of 
chronic migraine. In addition, biological processes and pathways impacted by administration of 




CHAPTER 2. GENE NETWORK DYSREGULATION IN THE TRIGEMINAL 
GANGLIA AND NUCLEUS ACCUMBENS OF A MIGRAINE MODEL 
 
Abstract 
 Migraine is a primary headache disorder that has detrimental impact on the patients’ life. 
Although intermittent administration of nitroglycerin (NTG) to mice can be used to model 
chronic migraine, the underlying molecular mechanism is not well understood. We compared the 
transcriptome from the trigeminal ganglia (TG) and nucleus accumbens (NAc) between control 
and NTG-treated mice. Among 110 genes presenting different patterns of expression between 
treatment and control groups among brain regions, Opalin, Slc32a1, and Penk were dysregulated 
in TG, while Cacna1b and H2-Eb2 were dysregulated in NAc. Among the 165 genes 
differentially expressed between the NTG and control groups across brain regions were Aldh1a1 
and Slc7a2. Glutamatergic and dopaminergic synapse were among the functional categories 
enriched among the differentially expressed genes. Our comparative transcriptome analysis offer 
insights for future migraine studies and the treatment of migraine. 
 
Introduction 
 Migraine is a life-long primary headache disorder and approximately 15% of adults 
worldwide experience painful or disabling migraines or severe headaches [1, 61]. Nitroglycerin 
(NTG), a donor of nitric oxide (NO) elicits headaches comparable in intensity, duration, and 
effect to migraine in humans [32]. Likewise, NTG triggers hyperalgesia in rodents and studies of 
the effect of NTG in mouse and rats have offered insights into the neurological and molecular 
mechanisms of migraine [40, 62-64]. Migraine is triggered by trigeminal ganglion nerves that are 
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sensitized and activated [65]. The nucleus accumbens (NAc) also participates in sensitization 
while receiving dopaminergic projections and serotonin innervations [66]. 
 Chronic intermittent administration of NTG to mice provides an effective model of 
chronic migraine  [67]. Under this model, mice exhibit acute mechanical hyperalgesia with each 
exposure and progressive and sustained basal hyperalgesia. The persistence of hyperalgesia after 
withdraw further confirmed the translational value of this model to understand the mechanisms 
of migraine and to support the development of therapies.  
 Despite the sound characterization of the effect of NTG on mechanical hyperalgesia, the 
molecular mechanisms underlying this effect are not well understood. A study of the trigeminal 
ganglia sampled from male rats at 30 and 90 min post NTG infusion uncovered 15 genes 
differentially expressed relative to controls [40]. These findings may reflect the acute 
hyperalgesia trigger used (one NTG infusion), sampling timeline, and brain region studied.   
 The objective of this study is to advance the understanding of the molecular disruption in 
a chronic hyperalgesia mouse model of migraine. Genes, biological processes and pathways 
prevalently impacted by chronic NTG exposure will be identified and perturbed gene and 
regulatory networks will be reconstructed. A comparative transcriptomic analysis of trigeminal 
ganglia and nucleus accumbens, will offer insights into their distinctive role of these brain 
regions associated with chronic headache disorders and migraine. 
 
Materials and methods 
 Experiments- Adult male C57BL6/J mice received food and water ad libitum and were 
maintained in a room with 12-h light-dark cycle. All experiments were approved by the Illinois 
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Institutional Animal Care and Use Committee. Management, drug administration, and sensory 
sensitivity testing followed our proven protocols [67]. Chronic hyperalgesia was modeled using 
intraperitoneal injections of NTG (10 mg/kg) every second day for 9 days on NTG-treated mice. 
Control (CON) mice received intraperitoneal injections of a vehicle solution (0.9% saline) 
following the same dosage (10mg/kg) and schedule as the NTG-treated mice. The NTG injection 
was prepared daily from a stock solution of 5.0 mg/mL NTG in 30% alcohol, 30% propylene 
glycol and diluted in 0.9% saline. Sensory sensitivity testing consisted in punctate mechanical 
stimuli applying the up-and-down method [67]. Licking, lifting or shaking of the hind paw after 
exposure to von Frey filaments was recorded as indicators of mechanical hyperalgesia.  
 RNA extraction and sequencing- Tissues were harvested approximately 24 h after the 
last NTG or vehicle injection. Mice were anesthetized and euthanized by perfusion. Brains were 
extracted and the trigeminal ganglion (TG) and nucleus accumbens (NAc) were rapidly 
dissected, snap-frozen, and stored at -80ºC.  Total RNA was obtained from individual mouse and 
brain region following manufacturer’s instructions. Steps included tissue homogenization with 
TRIzol (Invitrogen, USA) and ceramic beads (MO BIO, Carlsbad, USA), and isolation using the 
RNA-kit for isolation (Omega Biotek, Norcross, GA). All 20 samples (n=10 mice/treatment; 2 
brain regions/mice) had RIN values above 7.5. Paired-end reads 100nt in length were sequenced 
using the Illumina HiSeq 4000 platform. The average Phred quality score of the reads was 
assessed using FastQC [68] 
 RNA quantification and differential expression analysis- The paired-end reads were 
mapped to the C57Bl/6J mouse genome (version GRCm38) downloaded on October 2016 from 
NCBI [69]. The software Kallisto [52] was used to quantify the abundance of the transcript 
isoforms into counts and the R package (tximport [70]) was used to combine these counts 
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together with mapping information to quantify gene expression. Gene expression measurements 
were analyzed using a linear model including the main factors of NTG treatment and brain 
region and the interaction between NTG treatment and brain region with the software program 
edgeR [55]. All genes that had 5 or more reads per treatment-brain region group were analyzed 
to ensure adequate representation across groups. The Benjamini-Hoechberg false discovery rate 
(FDR) was used to adjust the differential expression P-value for multiple testing [71-75]. 
 Functional enrichment and network inference- The enrichment of functional 
categories among the genes most differentially expressed was explored. The categories studied 
included Gene Ontology (GO) Biological Processes (BP); and Molecular Function (MF) and 
KEGG pathways. Enrichment from two complementary approaches was evaluate; one analysis 
was based on a list of differentially expressed genes, while the other analysis was based on all 
genes and expression differential information. For the first approach, genes differentially 
expressed were analyzed using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID Version 6.8) [58]. The Mus musculus genome was used as background for 
testing and the Direct GO terms in DAVID was used to enhance the information by using the GO 
category identification in the repository. Enrichment of each category was assessed using 
Expression Analysis Systematic Explorer (EASE) score computed using a one-tailed jackknifed 
Fisher hypergeometric exact test. Interpretation was further facilitated by functional annotation 
clustering of categories. The statistical significance of each cluster of categories was assessed 
using an Enrichment Score (ES) computed as the geometric mean (in -log10 scale) of the EASE 
scores of member categories in the cluster [72-74, 76].  
 Additional insights into the functional categories impacted by the treatment and brain 
region studies were gained using the Gene Set Enrichment Analysis (GSEA) approach 
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implemented in the software package GSEA-P (version 2.0) [59]. The GSEA-P approach 
assesses the enrichment of functional categories in the Mus musculus Molecular Signature 
Database (MSigDB) calculating ES based on the maximum deviation of cumulative sum from 
the gene-phenotype correlation.  
 Genes exhibiting significant interaction between NTG treatment and brain region, 
significant NTG main effect, and significant brain region main effect were queried as potential 
targets of enriched transcription factors (TFs). This analysis was completed using the iRegulon 
[60] plugin in the Cytoscape environment [77]. The differentially expressed genes were searched 
against the database of target genes ranked according to the associated TF motifs. The TF 
normalized enrichment score (NES), computed based on the Area Under the cumulative 
Recovery Curve obtained from the database search, was used to assess the TF enrichment.  
 
Results and discussion 
 Summary of RNA-Seq measurements- Approximately 3 billion reads were generated 
across all 20 samples and approximately 70 million paired-end sequence readings were obtained 
per sample. No statistical difference in the number of mapped reads was detected between 
sample groups. The nucleotide quality score was > 30 across read positions. The read sequences 
were deemed of high quality and were not trimmed. The average percentage of the reads mapped 
to the mouse transcriptome was approximately 82% (± 4%). The effects of the interaction 
between treatment and brain region, and the main effects of treatment and brain region were 
analyzed on 22,071 genes after filtering low counts. 
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 Nitroglycerin treatment-by-brain region interaction effect on gene expression- Novel 
insights into the distinct response to NTG treatment between the NAc and TG are supported by 
the identification of 110 genes exhibiting significant (P-value ≤ 0.005) interaction effect. A list 
of 33 genes exhibiting most significant interaction effects (P-value ≤ 0.0005) is provided in 
Table 1. The majority of the genes exhibiting interaction effects (97 genes) were differentially 
expressed between the NTG and CON treatment groups in the TG whereas 13 genes were 
differentially expressed between the treatments in the NAc. This result is consistent with present 
understanding that migraine headache is related to the abnormal pain signaling of the trigeminal 
nucleus [78]. Similarly, a single NTG treatment triggered differential expression in 15 genes in 
the trigeminal ganglia of rats [40]. The higher number of genes impacted by NTG in the present 
study may be associated with the chronic NTG treatment evaluated. 
 Three main patterns can be identified among the genes exhibiting an interaction effect. 
One pattern is opposite differential expression between treatments across brain regions. Among 
the 87 genes exhibiting this pattern, 64 genes were over-expressed in the NTG treatment within 
the TG while 23 genes were under-expressed in mice receiving the NTG treatment within the 
TG. 
 Among the highest over-expressed genes in to the TG of NTG-treated relative to CON 
mice was oligodendrocytic myelin paranodal and inner loop protein (Opalin). This finding could 
support reports of altered myelin patterns in migraineurs since Opalin encodes one of the 
components of myelin [79]. Solute carrier family 32 (Gamma Amino Butyrate –GABA- 
vesicular transporter) member 1 (Slc32a1 also known as Vgat) was also over-expressed in the 
TG of NTG-treated relative to CON mice. Our finding is consistent with the use of Slc32a1 as a 
marker for GABAergic neurons and GABAergic communication across mouse peripheral 
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sensory ganglia modulates transmission of pain-related signals from the peripheral sensory 
nerves to the central nervous system [80].  Our identification of GABA-related genes 
dysregulated in response to the hyperalgesia-eliciting NTG treatment is also connected with the 
use of Valproic acid to disrupt the GABA pathway [81]. In addition to the GABA pathway, 
Slc32a1 belongs to the Morphine addiction, Nicotine addiction, and endocannabinoid signaling 
pathways. The over-expression of Slc32a1 in the TG of NTG-treated mice support concerns that 
of use of opioids to (e.g. to manage other conditions) causes development or worsening of 
migraine symptoms.  
 Preproenkephalin (Penk) was also over-expressed in the TG of NTG-treated relative to 
CON mice. Penk is a neuropeptide that plays a role in perception and pain recognition.  Penk 
produces opioid peptides, leucine- and methionine-enkephalin, which affects chronic tension-
type headaches [82, 83]. This neuropeptide increases the release of glutamate release in the NAc 
and decreases the concentration of GABA [84] in agreement with the solute carrier profiles 
identified in the present study. Our finding of Penk over-expression in the NTG group and 
established positive relation with glutamate is consistent with reports that chronic migraine 
exhibit increased glutamate transmission through its receptors expressed in the brain [85]. 
Moreover, this molecular signal is thought to contribute to the increase and maintenance of other 
sensory neuropeptides such as substance P (a member of the tachykinin neuropeptide hormone 
family) and calcitonin gene-related peptide (CGRP) that are also associated with migraine [86]. 
Another gene over-expressed in the TG of NTG-treated mice was RAR-related orphan receptor 
beta (Rorb). These gene lays a role in regulation of circadian rhythm and other rhythmic 
processes. Several studies have shown that dysregulation of sleep and circadian rhythm can 
cause migraine headache [87-89].  
 18 
 
 Among the genes over-expressed in the NAc of NTG-treated mice were calcium channel, 
voltage-dependent, N type, alpha 1B subunit (Cacna1b) and histocompatibility 2 (class II) 
antigen E beta2 (H2-Eb2). Mutations in Cacna1 have been associated with familial hemiplegic 
migraine [13]. Neuropeptide-like protein C4orf48 homolog (Gm1673) was also under-expressed 
in the NAc of NTG-treated relative to CON mice. Differential expression of this gene is 
associated with photoreceptivity [90] and migraineurs hypersensitivity to stimuli such as light, 
sound touch and odor [91]. This gene has been detected in most cortical and subcortical regions 
of the mouse brain [92].  
 The second pattern among genes exhibiting significant treatment by brain region 
interaction is a consistent relative expression between treatments albeit the significance level 
differed between brain regions. All 21 genes exhibiting this pattern were more over-expressed in 
the TG than in the NAc of mice receiving the NTG treatment. This result confirms the 
preponderance of the role of TG in hyperalgesia, headaches, and migraine. Genes exhibiting this 
pattern included POU domain, class 3, transcription factor 3 (Pou3f3), erb-b2 receptor tyrosine 
kinase 4 (Erbb4), solute carrier family 1 (glial high affinity glutamate transporter), member 2 
(Slc1a2). These findings are supported by previous reports. Knockout mouse for a POU domain 
had retina defects. ErbB4 is mainly expressed in the GABAergic interneurons of the cerebral 
cortex and is a receptor of neuregulin which is associated with the activation of neuropathic pain 
[93]. Slc1a2 was associated with migraine on a study of approximately 200 patients [94]. 
 The gene coding for the neuropeptide natriuretic peptide type C (Nppc) was significantly 
over-expressed in the TG of mice receiving the NTG treatment but was not differentially 
expressed in the NAc. Our finding confirms reports that natriuretic peptides play a role in 
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migraine events. Natriuretic peptides have an effect on the cerebral hemodynamics which plays a 
causal role in migraine [95, 96]. 
 The final pattern among the genes exhibiting an interaction effect was characterized by 
significantly different expression in one tissue while no expression in another tissue. No genes 
were solely differentially expressed in TG and the two long noncoding RNA genes (Gm15738 
and Gm39717) significantly over-expressed in response to NTG treatment within the NAc genes 
are yet to be annotated.  
 Functional analysis of the genes exhibiting Nitroglycerin-by-brain region interaction 
effects- Clusters of functional categories that were enriched among the genes exhibiting 
treatment by brain region interaction were uncovered using DAVID (Table 2). Two clusters of 
enriched GO BP and MF associated with positive regulation of transcription (enrichment score = 
1.8 and 1.5, respectively) were identified. This finding is consistent with the established 
association between activation of the transcription factor NF-kB in an animal model of migraine 
[97, 98]. 
 Complementary functional analysis using GSEA used information on differential 
expression between NTG and CON treatments within brain region. Tables 3 and 4 present the 
most significantly (P-value < 0.005; normalized enrichment score > |1.7|) enriched and relevant 
functional categories in TG and NAc respectively. Within TG enriched  categories among the 
genes over-expressed in the NTG group include: adaptive immune response (BP GO:0001913; 
GO:0002449; GO0019724; GO:0002460); regulation of glucose metabolic process (BP 
GO:0010906); pituitary gland development (GO:0021983); and visual and light perception 
(GO:00076601; GO:0050953); and retina processes (BP GO:0060041, GO:0060042; 
GO:0003407). Within TG, the association observed in this study between chronic NTG-
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treatment and the immune process T cell mediated cytotoxicity was also reported in the TG of 
rats in response to acute NTG-treatment [40]. The observed enrichment of glucose metabolism 
(BP GO:0010906) is consistent with understanding that GABA-receptors are involved in the 
regulation of glucose homeostasis [99] and we also uncovered (Table 1) GABA processes-
associated genes (Slc32a1, Penk) differentially expressed between NTG-treated and CON mice.  
 The enrichment of sensory perception of light stimuli and visual perception categories 
among the genes over-expressed in NTG-treated mice are in agreement with the hypersensitivity 
to sensory stimuli and photophobia (exacerbation of headache by light) experienced by 
migraneurs [100]. The association between NTG and retina development genes prompt us to 
postulate that chronic NTG may also trigger retinal migraine and studies are needed to assess the 
incidence of this type of migraine that is different from the headache-type of migraine modeled 
in this study. Lastly, the enrichment of the pituitary gland category among genes over-expressed 
in NTG-treated mice is consistent with reports that pituitary disruptions are associated with 
disabling headaches [101]. Our finding offers new insights into the mode of action of chronic 
NTG treatment that elicits hyperalgesia. Among the categories enriched among the genes under-
expressed in the TG of NTG-treated mice was MF magnesium ion binding (GO:000287). Our 
finding supports reports of abnormal concentration of magnesium in migraineurs [102].   
 An insightful finding is the enrichment of innate immune response category 
(GO:0045087) among the genes under-expressed in the NAc of NTG-treated mice (Table 4). 
This is an interesting finding because meanwhile innate immune response is depressed in the 
NAc, adaptive immune response was enriched among the genes over-expressed in the TG of 
NTG-treated mice. This highlights the key interaction effect of brain region-by-NTG for immune 
response, one of the process associated with hyperalgesia. This brain-region dependent response 
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to NTG may be due to the unique and complementary role of each region and (or) a direction of 
limited resources to support one set of immune process (adaptive) over another (innate). Another 
category enriched among the genes under-expressed in the NTG group was regulation of reactive 
oxygen species (GO:2000377). This finding offers insights into the mouse brain’s natural 
attempt to ameliorate the hyperalgesia triggered by NTG because this chemical compound is a 
nitric oxide (NO) donor and chemical inhibition of NO synthase (NOS) is used to treat migraines 
[37]. 
 A compelling finding is that, consistent with TG, enriched categories among the genes 
over-expressed in the NAc of NTG mice include detection of stimulus involved in sensory 
perception (GO:0050906, GO:0051606; GO:0009581). These categories are consistent with the 
enrichment in visual and light perception and retinal processes in the TG. This result supports the 
preposition that certain migraine symptoms are supported by related biological processes across 
brain regions. The glutamate receptor signaling pathway (GO:0007215) was also enriched 
among the genes over-expressed in the NAc of NTG-treated mice. This result is consistent with 
the significant NTG-by-region interaction effect on Penk and Slc1a2, two genes associated with 
the glutamate pathway. The differential expression of individual genes and enrichment of the 
glutamate pathway observed in this study supports reports of association between glutamate and 
migraine [85].  
 Our study identified genes and processes that are distinctively dysregulated in TG relative 
to NAc in response to chronic NTG treatment. Immune-response functions were enriched in the 
TG among the genes over-expressed in NTG-treated mice whereas enrichment of regulation of 
reactive oxygen species in the NA among the genes under-expressed in NTG-treated mice. Our 
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results suggest that the molecular mechanisms underlying migraine and the discovery of 
potential targets to ameliorate this disorder must be studied on a brain region-specific manner. 
 Main effect of Nitroglycerin treatment on gene expression- Differential gene 
expression in response to NTG treatment across brain regions (main effect of NTG) was 
investigated. The 165 genes were differentially expressed between the NTG and CON groups. 
Among the genes, the 22 genes exhibiting significant (P-value ≤ 0.0005) NTG effect are listed in 
Table 5. 
 The majority of the 22 differentially expressed genes (82%) were over-expressed in 
NTG-treated relative to CON mice and the same distribution (86%) was observed on the 
expanded list of 165 genes. Among the genes with highest over-expression in mice exposed to 
NTG was Aldehyde Dehydrogenase 1 Family Member A1 (Aldh1a1). Aldehyde dehydrogenases 
catalyze oxidation in many pathways including the conversion of NTG into NO, a compound 
that acts as vasodilatator [103]. Nitric oxide triggers headaches and chemical inhibition of NOS 
is an effective treatment to relieve migraine attacks[37]. Furthermore the migraine treatment 
Valproic acid inhibits the activity of the aldehyde dehydrogenase Aldh5a1 [81]. The association 
between NTG and over-expression of Aldh1a1 is also consistent with our prior finding of 
enrichment of regulation of reactive oxygen species among the genes under-expressed in the 
NAc of NTG-treated mice (Table 4).  
 Another gene highly over-expressed in NTG-treated mice irrespective of brain region 
was solute carrier family 7 cationic amino acid transporter, y+ (Slc7a2; Table 5). This gene plays 
a role in NO production involved in inflammatory response and amino acid (e.g. arginine, lysine, 
and ornithine) transport.  This protein coded by this gene transports arginine and arginine is a 
chemical precursor to NO that acts as a substrate for NO synthase [104].  
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 Both Slc7a2 and Slc32a1 belong to the same family of genes involved in transmembrane 
transport of small molecules and while Slc7a2 was impacted by NTG in a brain region 
independent manner, Slc32a1 exhibited a brain region-dependent effect of NTG treatment (Table 
1). Our findings demonstrate the opportunity to explore both individualized therapies that can 
address either general or brain-region specific migraine and broad therapies within the same 
region.  
 The circadian rhythm period Per3 gene was over-expressed in NTG-treated relative to 
CON mice (Table 5). The association between Per3 and cluster headache has been recommended 
[105]. The study of the effect of acute NTG treatment in the TG of rats uncovered over-
expression of Per1, another gene in the period family [40] although no significant differential 
expression on Per3 was observed. Another gene over-expressed in NTG-treated mice was Ctla2b 
and this finding is in agreement with a patent claim that this gene is associated with pain and can 
be used for diagnosis of algesia [106]. 
 An interesting discovery from our study is that 5-hydroxytryptamine (serotonin) receptor 
5B (Htr5b) was under-expressed in NTG-treated relative to CON mice (Table 5). Serotonin is a 
neurotransmitter that regulates neural function and migraines are associated with disruption in 
the serotonergic system [107, 108].  The provocative aspect of this finding is that the under-
expression of Htr5b worsens hyperalgesia in a manner synergistic and complementary to the 
vasodilatation mode of action of Aldh1a1 (Table 5).  
 Triptans are widely used to treat migraine because these compounds not only activate 
serotonin receptor thus enhancing the serotonin signal but also constrict blood vessels and inhibit 
the release of neuropeptides such as substance P and CGRP [109]. Our results demonstrates that 
the chronic NTG treatment used in our mouse model is capable of multi-modal triggering of 
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hyperalgesia. Another gene over-expressed in NTG-treated relative to CON mice was inositol 
1,4,5-trisphosphate receptor type 2 (Itpr2). Over-expression of this gene has also been associated 
with induced visceral inflammatory hypersensitivity [110] and also in rat models of traumatic 
and HIV-associated neuropathic pain [111].  
 Non-coding RNA sequences including A930013F10Rik and 1700024F13Rik were over-
expressed in NTG-treated relative to CON mice. This finding offers evidence on the role of 
epigenetic regulation that underlie susceptibility to primary headache disorders. The potential 
role of non-coding RNA on migraines has been suggested and the example of the regulation of a 
glutamate transporter of the glutamatergic system by non-coding RNA has been presented in 
support of this hypothesis [112].  
 Functional analysis of the genes exhibiting Nitroglycerin treatment effects- The most 
significant DAVID clusters of functional categories enriched among the genes differentially 
expressed between NTG-treated and CON mice are presented in Table 6. One critical cluster 
includes the KEGG pathways glutamatergic synapse (mmu04724) and dopaminergic synapse 
(mmu04728) and the GO BP rhythmic process (GO:0048511).  Supporting our results of 
enrichment of rhythmic processes associated with NTG treatment (Table 6), migraine symptoms 
have been associated with dysregulation of circadian rhythm [113]. The enrichment of 
glutamatergic synapse among genes differentially expressed in response to NTG (Table 6) is 
consistent established positive association between increased levels of glutamatergic 
transmission, heightened and stable levels of sensory neuropeptides such as substance P and 
CGRP, and chronic migraine symptoms [32]. The observed enrichment in the glutamatergic and 
dopaminergic pathways agrees with the understanding that dysregulation levels of the 
neurotransmitters serotonin, dopamine, and noradrenalin and the neuromodulators tyramine, 
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octopamine and synephryne in the dopaminergic and noradrenergic synapses trigger TG to 
release neuropeptides CGRP and substance P. This process elicits the build-up of inflammatory 
milieu, the sensitization of TG and the migraine event [114]. 
 The link between chronic NTG hyperalgesia and the dopaminergic system identified in 
this study (Table 6) also advances the understanding of the relationship between drug abuse and 
migraine. The dopaminergic system modulates both the transmission of pain perception and also 
drug reward and addiction [115]. Dopamine receptor 4 has been associated with migraine 
symptoms without drug addiction, dopamine transporter has been associated with migraine 
associated with drug abuse. 
 Another enriched functional cluster among genes differentially expressed in response to 
NTG centers around protein phosphorylation (BP GO:0018108), ATP binding (MF 
GO:0005524), and kinase activity (MF GO:0004672). Phosphorylation modulates neuronal 
function and the observed enrichment is consistent with the association between mutations that 
inhibit the phosphorylation of ATPases and hemiplegic migraine [116]. Both our findings of 
under-expressed serotonin receptor and phosphorylation enrichment in the NTG-treated mice can 
be related to a report that serotonin depletion in rats increases nociception-evoked 
phosphorylation in the TG of the NR1 subunit of N-methyl-D-aspartate (NMDA) receptor [117]. 
This molecule increases neuronal excitability that is characteristic of migraine in rats. The 
enrichment of ion transport processes (Table 6) among the genes differentially expressed 
between NTG-treated and CON mice (BP GO:0006811) is confirmed by a study of hemiplegic 
migraine. Polymorphisms in genes coding for ion transport molecules were associated with this 
disorder [13, 118-120]. 
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 Results from the GSEA functional analysis within genes over- and under-expressed in 
NTG-treated relative to CON mice offered complementary insights into the impact of chronic 
NTG treatment.  Table 7 present the most significantly (P-value < 0.0005; normalized 
enrichment score > |1.8|) enriched and relevant functional categories. Nucleoside binding was 
enriched among the genes under-expressed in NTG-treated mice across both brain regions (Table 
7) and specifically in TG (Table 3). Modulators of G protein-coupled receptor (GPCRs) are used 
to treat pain and migraine and a class of these have nucleoside binding capabilities [121]. 
 Consistent with the ion transport enrichment identified by DAVID, anion transmembrane 
transport (BP GO:0098656; Table 7) was significantly enriched among the genes over-expressed 
in NTG-treated relative to CON mice. The GSEA analysis was able to narrow down this 
transport to L-alpha-amino acid. (BP GO:0015807) and L-glutamic acid is an important source 
of GABA. Our investigation of functional categories potentially impacted by chronic NTG 
treatment across brain regions offered insights into the potential key role of signaling molecules 
in the glutamatergic, dopaminergic, and circadian rhythm systems. Our results also suggest that, 
in addition to brain-region specific, some molecular mechanisms underlying migraine have 
similar patterns across brain regions. 
 Main effect of brain region on gene expression between brain regions- The 
differential expression of genes between TG and NAc was studied for completeness and as 
reference. Supporting the different roles of both brain regions, 361 genes were differentially 
expressed at P-value < 5 x 10-10 and log fold change > |4| and 37% of these genes were over-
expressed in TG relative to NA. Among 361 genes, top 20 most significantly (P-value < 1.0E-
10) differentially expressed genes were listed in Table 8. Table 9 presents the most significantly 
DAVID clusters (enrichment score > |1.7|) of selected and relevant enriched categories. The most 
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enriched categories within the top clusters include: ion transport channel activity (MF 
GO:0005216; enrichment score = 6); neuroactive ligand-receptor interaction (KEGG 
mmu04080; enrichment score = 5.3); and endocannabinoid signaling (KEGG mmu04723; 
enrichment score = 3.1). The enrichment of these categories are in agreement with the known 
role of both brain regions in the context of hyperalgesia and migraine. Connecting the cranial 
vasculature to the central nervous system, TG releases CGRP and other neuropeptides and 
sensory signals in response to NO. This process triggers vasodilation and neurogenic 
inflammation that elicit hyperalgesia, sensitization, and allodynia [122]. The signals from TG 
reach other brain regions including the NAc, a ventral extension of the striatum that is involved 
in the integration information related to cognitive, sensory, and emotional processing. 
Consequently, the disruption of the NAc processes by TG signals play a role in migraine and 
hyperalgesia comorbidities including depression, irritability, fatigue, sleepiness, and loss of 
appetite [123]. The study of the effect of interaction between NTG treatment and brain region on 
gene expression enable the identification genes dysregulated in a brain region-dependent manner 
whereas the study of the main effect of NTG treatment uncovered genes that were consistently 
dysregulated across brain regions. 
 Regulatory networks- Regulatory network analysis further aided in the identification of 
TFs that regulate target genes dysregulated by NTG treatment. Table 10 lists the enriched TFs 
(normalized enrichment score > 3.0 corresponding to approximate 3% < FDR < 9% [60]) among 
the genes differentially expressed (P-value < 0.005) in the TG (338 genes), in the NAc (103 
genes), and across both brain regions (166 genes) between NTG-treated and CON mice. The role 
of many of the TFs in on chronic hyperalgesia uncovered in this study (Table 10) have been 
suggested for correlated phenotypes and processes in other studies. Figures 1, 2 and 3 depict the 
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relationship between the TFs most enriched (normalized enrichment score > 3.5 and < 40 genes 
to facilitate visualization) among genes differentially expressed (P-value < 0.005) within TG, 
NAc, and across brain regions, respectively. The thresholds were used to facilitate the 
visualization of relationships between TFs and between TFs and their target genes. 
 Among the TFs enriched amid the genes dysregulated in the TG of NTG-treated mice, 
CCAAT/Enhancer Binding Protein Alpha (Cebpa; normalized enrichment score = 5.2) and small 
muscle protein, X-linked (Smpx; normalized enrichment score = 4.4) were enriched in the TG 
(Table 10). Cebpa siRNA has been associated with attenuation of pain hypersensitivity in the 
spinal cord of mice [124]. In mice, Smpx is dysregulated by disruption of Neurolysin, a molecule 
implicated in pain control and blood pressure regulation, two processes associated with 
hyperalgesia [125]. 
 A notable finding in the TG regulatory network disrupted by NTG depicted in Figure 1 is 
the connection between all four enriched TFs through other TFs that differentially expressed.  
The TFs Snrnp70, Smad1, Pax6 and Cebpa are connected through the TF oligodendrocyte TF 1 
(Olig1) and NK2 homeobox 2 (Nkx2-2 or Nkx2.2). TF Olig1 was over-expressed in NTG-
treated relative to CON mice in TG [Log2(NTG/CON) = 1.30; P-value < 0.0032] and TF Nkx2-2 
was over-expressed in the TG of NTG-treated relative to CON mice [(Log2(NTG/CON) =1.88; 
P-value < 0.026)]. The key role of Nkx2-2 on the response of TG to NTG identified in this is 
study is consistent with the expression of this gene in cells that give rise to serotonergic neurons 
[126]. Olig1 proteins are expressed in cells that give rise to inhibitory γ-aminobutyric acid-
containing (GABAergic) interneurons that attenuate neuropathic pain when transplanted to 
rodents [127]. Several genes targets of the enriched TFs in TG in Figure 1 exhibited significant 
treatment-by-brain region effect (Table 1) including: CaM kinase-like vesicle-associated 
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(Camkv), egl-9 family hypoxia-inducible factor 2 (Egln2), WSC domain containing 1 (Wscd1), 
and stathmin 4 (Stmn4).  
 Among the TFs enriched amid the genes dysregulated in the NAc of NTG-treated mice 
(Table 10), direct IAP-binding protein with low PI (Diablo; normalized enrichment score = 
4.81), yin and yang 1 (Yy1; normalized enrichment score = 4.34) were enriched in NAc. The 
transcriptional regulator Smac/Diablo is elevated in rats treated with Khat (alkaloid compounds) 
that have been associated with migraine events [128]. Yy1 was enriched among genes of 
inflammatory pathways dysregulated in a transgenic mouse model of migraine [129]. Figure 2 
highlights the interconnection between several enriched TFs that have been previously associated 
with migraine or pain. Six6 is associated with eye development and open-angle glaucoma, an 
hereditary disorder that includes migraine as one of its symptoms [130]. Also, the TF doublesex- 
and mab-3-related transcription factor C1 (Dmrtc1) and regulatory factor X, 2 influences HLA 
class II expression (Rfx2) have been proposed as biomarkers for ischemic attacks and strokes. 
These disorders share symptoms with migraine with aura such as visual disturbances, speech 
impairment, and muscle weakness [131]. The fewer number of differentially expressed genes 
between NTG-treated and CON mice in NAc relative to TG explains the fewer number of genes 
in Table 1 that are present in Figure 2 including H2A histone family member Z (H2afz). 
Dysregulation of H2afz has been associate with effects of substances of abuse such as alcohol 
and nicotine [132, 133] and drug abuse has been in turn associated with migraine events [134]. 
 Amid the TFs enriched among the genes dysregulated in NTG-treated mice across brain 
regions (Table 10), E2F Transcription Factor 1 (E2f1; normalized enrichment score = 5.1) and 
BarH-like homeobox 1 (Barx1; normalized enrichment score = 4.5) were enriched among the 
genes differentially expressed between NTG-treated and CON mice across both brain regions. 
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Although these TFs were not differentially expressed in the corresponding test, E2f1, Barx1 and 
other TFs have been associated with migraine-related processes and genes differentially 
expressed in this study.  E2f1 was dysregulated in a rat model of neuropathic pain and migraine 
pain is considered a unique neuropathic pain [135]. The expression of Nkx2-2 (TF enriched in 
the TG network) and Gata3 have a strong positive correlation and Gata3-deficient mice fail to 
initiate serotonin synthesis [136]. A large number of target genes in Figure 3 were among the 
most differentially expressed genes between NTG-treated and CON mice listed in Table 5 
including: Aldh1a1, Per3, Slc7a2, serotonin receptor Htr5b, sphingosine 1-phosphate receptor 3 
(S1pr3), ubinuclein-2 (Ubn2), tubulin polyglutamylase (Ttll4), inositol 1,4,5-trisphosphate 
receptor type 2 (Itpr2). This result highlights the critical role of TFs in the dysregulation of genes 
associated with NTG-treatment.  
 The effect of the NTG treatment on the TF Nuclear factor kappa-B was not definite. 
Nuclear factor kappa-B p100 subunit (Nfkb2) was over-expressed in NTG-treated relative to 
CON (10.85/10.23) whereas nuclear factor kappa-B p105 subunit (Nfkb1) was under-expressed 
in NTG-treated relative to CON mice (42.69/44.09). Also, Nfkb was not represented among the 
192 target genes considered for regulatory analysis. The weak association between Nfkb and 
NTG-treatment does not support a report of the role of this transcription factor on migraine. One 
NTG treatment elicited activation of Nfkb 4 hours later measured using immunohistochemical 
and Western blot techniques [97]. The reported effect of acute NTG treatment of rats on Nfkb at 
the protein level 4 hours later does not reach the same level of significance in chronic NTG 
treatment of mice at the gene expression level 24 hours later. Moreover, Nfkb activates Sox9 
[137], a TF that regulates the expression of many of the 192 genes differentially expressed 
between NTG-treated and CON mice in this study. 
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Another notable findings is that the TFs in the regulatory network disrupted by NTG in 
TG are less connected by common target genes than the regulatory networks disrupted in NAc 
(Figure 2) or across brain regions (Figure 3).  This observation can have implications in the 
identification of effective targets to alleviate chronic hyperalgesia or migraine albeit it may also 
be affected by the criteria used to select the TFs depicted. The lower level of interconnection 
among TFs and targets genes observed in TG suggest that a larger number of targets may be 
needed to effectively revert the network disruption. Overall, our study of regulatory networks 
impacted by NTG-treatment confirmed our finding in Table 2 on the important role of 
transcriptional regulation on the chronic NTG model of migraine. 
Conclusions 
Here, we performed a comparative transcriptomic analysis of two brain regions, TG and NAc, 
using a predictive animal model with relevance to chronic migraine pathogenesis. To our 
knowledge, this is the first transcriptome analysis performed using a chronic migraine model.   
Analyzing transcriptional changes and their functional analysis, we discovered that many genes 
with immune response and pain related terms showed brain region-specific expression patterns 
under NTG treatment. Our results suggest that the understanding of molecular mechanisms of 
chronic migraine and the discovering potential targets to ameliorate migraine headache must be 
conducted by a brain region-specific manner. 
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Figure 1. The regulatory network between the most enriched (normalized enrichment score > 3.5 
and < 40 genes to facilitate visualization) TFs and their target genes which are differentially 








Figure 2. The regulatory network between the most enriched (normalized enrichment score > 3.5 
and < 40 genes to facilitate visualization) TFs and their target genes which are differentially 








Figure 3. The regulatory network between the most enriched (normalized enrichment score > 3.5 
and < 40 genes to facilitate visualization) TFs and their target genes which are differentially 






Table 1. Genes exhibiting significant (P-value < 0.0005) Nitroglycerine treatment by brain region interaction effect. 













Gm31690 1.3E-08 3.0E-04 -0.09 2.31 -5.52 -3.09 -3.18 -5.43 
C030029H02Rik 1.7E-07 1.9E-03 -0.17 2.00 -5.94 -3.80 -3.97 -5.77 
Lrrc8a 6.5E-07 3.6E-03 0.11 -0.18 1.18 0.86 0.97 1.07 
Cdr2l 3.5E-06 9.7E-03 0.15 -0.16 2.89 2.55 2.70 2.74 
Gm39080 1.7E-05 4.1E-02 0.13 1.81 -4.44 -2.79 -2.65 -4.57 
AW047730 1.9E-05 4.3E-02 0.06 1.77 -5.88 -4.19 -4.13 -5.93 
BC006965 2.7E-05 5.5E-02 -0.17 1.68 -3.68 -1.86 -2.02 -3.51 
Opalin 3.3E-05 5.5E-02 -0.20 2.02 -7.22 -5.02 -5.22 -7.01 
A230001M10Rik 4.1E-05 6.5E-02 -0.14 1.09 -3.72 -2.50 -2.65 -3.57 
Scrg1 5.7E-05 7.8E-02 0.06 1.44 -5.46 -4.09 -4.03 -5.52 
Gm39673 7.0E-05 8.1E-02 -0.07 0.57 -0.67 -0.06 -0.12 -0.59 
Gm10052 9.4E-05 9.9E-02 -0.13 1.05 -2.23 -1.07 -1.21 -2.09 
Gm29907 1.0E-04 1.0E-01 0.53 -0.40 -0.24 -1.19 -0.66 -0.76 
Rpl23 1.4E-04 1.2E-01 -0.23 0.23 -0.28 0.15 -0.07 -0.05 
Gm39728 1.5E-04 1.2E-01 0.79 -0.82 -0.08 -1.71 -0.92 -0.86 
Ccdc190 1.5E-04 1.2E-01 -0.23 0.73 -3.45 -2.51 -2.74 -3.21 
Neu4 1.5E-04 1.2E-01 0.02 1.43 -4.97 -3.56 -3.54 -4.98 
Gm42386 1.6E-04 1.2E-01 -0.12 0.95 -3.32 -2.27 -2.39 -3.19 
Camkv 1.6E-04 1.2E-01 0.02 0.67 -7.75 -7.13 -7.11 -7.77 
H2afz 1.7E-04 1.2E-01 -0.23 0.09 -0.48 -0.19 -0.41 -0.25 
Slc32a1 2.1E-04 1.4E-01 -0.03 1.94 -9.26 -7.32 -7.35 -9.22 
Gm20594 2.2E-04 1.4E-01 -0.08 0.31 -3.31 -2.95 -3.03 -3.23 
Efnb3 2.2E-04 1.4E-01 -0.10 0.76 -4.20 -3.36 -3.46 -4.09 
Stmn4 2.6E-04 1.6E-01 -0.12 0.28 -2.37 -2.00 -2.12 -2.24 
Gm35040 2.9E-04 1.7E-01 0.12 1.47 -6.49 -5.15 -5.03 -6.61 
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Table 1. (cont.) 
Siglech 3.0E-04 1.8E-01 -0.08 0.56 -3.94 -3.32 -3.40 -3.85 
Wscd1 3.4E-04 1.9E-01 -0.08 1.01 -3.68 -2.62 -2.70 -3.60 
Tbcd 3.6E-04 2.0E-01 0.09 -0.13 1.82 1.58 1.67 1.74 
Egln2 4.0E-04 2.0E-01 0.09 -0.13 0.73 0.48 0.57 0.64 
Ttr 4.6E-04 2.2E-01 -1.28 4.72 -2.26 3.71 2.43 -0.98 
Tmem88b 4.6E-04 2.2E-01 -0.11 0.80 -2.92 -2.03 -2.14 -2.80 
aFalse Discovery rate adjusted P-value. 
bLog2(fold change) between two treatment-brain region groups: NTG=Nitroglycerine-treated mice; CON=Control mice; 













Table 2. Clusters of Gene Ontology (GO) categories enriched (enrichment score ES > 1.5) 
among genes exhibiting significant interaction effects identified using DAVID. 
GO Category GO Identifier and Name P-value 
aFDR P-
value 
Cluster 1 (ES: 1.8)    
bBP GO:0045893~positive regulation of transcription, DNA-templated 5.8E-03 7.4E-01 
MF GO:0003682~chromatin binding 2.7E-02 9.5E-01 
MF GO:0044212~transcription regulatory region DNA binding 3.4E-02 9.3E-01 
Cluster 2 (ES: 1.5)    
BP GO:0045893~positive regulation of transcription, DNA-templated 5.8E-03 7.4E-01 
MF GO:0003677~DNA binding 7.0E-03 8.9E-01 
MF GO:0043565~sequence-specific DNA binding 9.6E-03 7.8E-01 
BP GO:0006351~transcription, DNA-templated 2.2E-02 8.7E-01 
MF GO:0003700~transcription factor activity, sequence-specific DNA binding 7.8E-02 9.7E-01 
BP GO:0006355~regulation of transcription, DNA-templated 1.8E-01 9.8E-01 
BP GO:0045944~positive regulation of transcription from RNA polymerase II promoter 2.6E-01 9.9E-01 
aFalse Discovery rate adjusted P-value. 









Table 3. Enriched Gene Ontology (GO) category among genes differentially expressed between 
Nitroglycerine-treated and Control mice in the trigeminal ganglia identified using GSEA. 
aExpression




Under      
MF GO:0000287 magnesium ion binding -1.85 0.0E+00 6.4E-02 
MF GO:0001882 nucleoside binding -1.72 0.0E+00 2.4E-01 
Over      
BP GO:0060041 retina development in camera type eye 1.96 0.0E+00 4.8E-02 
BP GO:0021983 pituitary gland development 1.87 2.3E-03 1.2E-01 
BP GO:0001913 T cell mediated cytotoxicity 1.86 4.9E-03 8.3E-02 
BP GO:0060042 retina morphogenesis in camera type eye 1.86 0.0E+00 9.4E-02 
BP GO:0010906 regulation of glucose metabolic process 1.85 0.0E+00 7.1E-02 
BP GO:0002449 lymphocyte mediated immunity 1.82 0.0E+00 9.0E-02 
BP GO:0007260 tyrosine phosphorylation of STAT protein 1.81 6.9E-03 7.6E-02 
BP GO:0019724 B cell mediated immunity 1.76 0.0E+00 9.7E-02 
BP GO:0002460 adaptive immune response 1.75 0.0E+00 1.0E-01 
BP GO:0007601 visual perception 1.74 0.0E+00 1.0E-01 
BP GO:0050953 sensory perception of light stimulus 1.71 0.0E+00 1.3E-01 
aExpression: Over- and under-expressed in Nitroglycerin-treated relative to Control mice.  
bBP: biological process; MF: molecular function. 
cnormalized enrichment score. 









Table 4. Enriched Gene Ontology (GO) category among genes differentially expressed between 
Nitroglycerine-treated and Control mice in the nucleus accumbens identified using GSEA. 
aExpression




Down      
BP GO:2000377 regulation of reactive oxygen species metabolic process -1.76 0.0E+00 2.1E-01 
BP GO:0034341 response to interferon gamma -1.76 2.2E-03 1.6E-01 
BP GO:0045087 innate immune response -1.74 0.0E+00 1.7E-01 
Up      
BP GO:0060079 regulation of excitatory postsynaptic membrane potential 1.84 0.0E+00 1.0E-01 
BP GO:0051606 detection of stimulus 1.81 0.0E+00 1.4E-01 
MF GO:0005230 extracellular ligand gated ion channel activity 1.79 0.0E+00 1.2E-01 
BP GO:0007215 glutamate receptor signaling pathway 1.78 0.0E+00 9.4E-02 
BP GO:0009581 detection of external stimulus 1.76 0.0E+00 9.7E-02 
BP GO:0001964 startle response 1.69 5.4E-03 1.6E-01 
BP GO:0050906 detection of stimulus involved in sensory perception 1.69 5.5E-03 1.6E-01 
aExpression: Over- and under-expressed in Nitroglycerin-treated relative to Control mice.  
bBP: biological process; MF: molecular function. 
cnormalized enrichment score. 








Table 5. Genes exhibiting significant (P-value < 0.0005) Nitroglycerine treatment effect. 
Gene Symbol Gene Name aNTG-CON P-value 
bFDR P-
value 
Gm32234 PREDICTED: uncharacterized protein Gm32234 1.02 5.2E-06 1.1E-01 
Aldh1a1 retinal dehydrogenase 1 0.49 2.1E-05 2.3E-01 
Ctla2b protein CTLA-2-beta 0.54 3.4E-05 2.5E-01 
Gm33697  0.71 6.0E-05 2.9E-01 
Ttll4 PREDICTED: tubulin polyglutamylase TTLL4 0.15 9.1E-05 2.9E-01 
Per3 PREDICTED: period circadian protein homolog 3 0.22 9.5E-05 2.9E-01 
Itpr2 PREDICTED: inositol 1,4,5-trisphosphate receptor type 2 0.27 1.0E-04 2.9E-01 
Mfsd9 major facilitator superfamily domain-containing protein 9 -0.20 1.1E-04 2.9E-01 
Gm31045  -0.77 1.4E-04 2.9E-01 
Ubn2 ubinuclein-2 0.12 1.5E-04 2.9E-01 
A930013F10Rik 0.27 1.5E-04 2.9E-01 
Gm8149  0.81 1.7E-04 3.1E-01 
Gm32085  0.38 2.9E-04 4.4E-01 
Gm33272  0.62 3.0E-04 4.4E-01 
Gm31721  0.88 3.1E-04 4.4E-01 
Gm42162  0.51 3.3E-04 4.4E-01 
Slc7a2 cationic amino acid transporter 2 0.16 3.6E-04 4.4E-01 
1700024F13Rik 0.72 3.6E-04 4.4E-01 
Htr5b PREDICTED: 5-hydroxytryptamine receptor 5B -0.48 3.8E-04 4.4E-01 
Srrm4os  1.14 4.0E-04 4.4E-01 
Gm38900  0.75 4.2E-04 4.4E-01 
S1pr3 sphingosine 1-phosphate receptor 3 -0.17 4.6E-04 4.6E-01 
aLog2(fold change) between Nitroglycerine (NTG)-treated relative to Control (CON) mice. 









Table 6. Clusters of Gene Ontology (GO) categories enriched (enrichment score ES > 2.0) 
among genes differentially expressed between Nitroglycerine-treated and Control mice using 
DAVID. 
Category aGO Identifier and Name P-value bFDR P-value 
Cluster 1 (ES: 2.2)    
MF GO:0004713~protein tyrosine kinase activity 1.6E-04 4.1E-02 
BP GO:0018108~peptidyl-tyrosine phosphorylation 1.7E-04 1.3E-01 
MF GO:0004672~protein kinase activity 4.0E-04 9.8E-02 
BP GO:0006468~protein phosphorylation 7.4E-04 4.6E-01 
BP GO:0046777~protein autophosphorylation 1.1E-03 6.0E-01 
BP GO:0016310~phosphorylation 1.1E-03 6.1E-01 
MF GO:0005524~ATP binding 4.0E-03 6.5E-01 
Cluster 2 (ES: 2.1)    
KEGG mmu04724:Glutamatergic synapse 1.5E-04 1.8E-02 
BP GO:0048511~rhythmic process 2.2E-03 8.3E-01 
KEGG mmu04728:Dopaminergic synapse 3.0E-03 3.0E-01 
Cluster 3 (ES: 2.0)    
BP GO:0006811~ion transport 3.4E-03 9.4E-01 
MF GO:0005216~ion channel activity 5.9E-03 7.8E-01 
aBP: biological process; MF: molecular function; KEGG: KEGG pathway. 









Table 7. Enriched Gene Ontology (GO) category among genes differentially expressed (P-value 
< 0.0005) between Nitroglycerine-treated and Control mice using GSEA. 
aExpression/




Under      
MF GO:0001882 nucleoside binding -1.92 0.0E+00 2.3E-02 
MF GO:0035639 purine ribonucleoside triphosphate binding -1.88 0.0E+00 3.4E-02 
Over      
BP GO:0003333 amino acid transmembrane transport 1.81 1.7E-03 1.9E-02 
MF GO:0046943 carboxylic acid transmembrane transporter activity 1.81 0.0E+00 2.0E-02 
MF GO:0022804 active transmembrane transporter activity 1.81 0.0E+00 2.2E-02 
MF GO:0008509 anion transmembrane transporter activity 1.84 0.0E+00 1.5E-02 
BP GO:0098656 anion transmembrane transport 1.84 0.0E+00 1.6E-02 
BP GO:0006865 amino acid transport 1.84 0.0E+00 1.7E-02 
MF GO:0008514 organic anion transmembrane transporter activity 1.89 0.0E+00 4.3E-03 
BP GO:1902475 L alpha amino acid transmembrane transport 1.92 0.0E+00 1.5E-03 
MF GO:0015179 L amino acid transmembrane transporter activity 1.94 0.0E+00 1.2E-03 
BP GO:0015807 L amino acid transport 2.00 0.0E+00 0.0E+00 
aExpression: Over- and under-expressed in Nitroglycerin-treated relative to Control mice.  
bBP: biological process; MF: molecular function. 
cnormalized enrichment score. 




Table 8. Top 20 most significantly (P-value < 1.0E-10) differentially expressed genes under 
tissue effect (those of genes that logFC > 0 represent the expression of TG region is greater than 
that of NA region). 
Gene Symbol Gene Name aTG-NA 
Over  
Mrgprd MAS-related GPR, member D 9.74 
Mpz  9.51 
Isl2 insulin related protein 2 9.43 
Prph peripherin 9.37 
Acpp acid phosphatase, prostate 9.23 
Tmem233 transmembrane protein 233 9.22 
Gfra3 glial cell line derived neurotrophic factor family receptor alpha 3 9.21 
Tusc5 tumor suppressor candidate 5 9.11 
Scn10a sodium channel, voltage-gated, type X, alpha 9.10 
Pirt phosphoinositide-interacting regulator of transient receptor potential channels 8.99 
Ahnak2 AHNAK nucleoprotein 2 8.97 
D130009I18Rik RIKEN cDNA D130009I18 gene 8.93 
Pou4f1 POU domain, class 4, transcription factor 1 8.90 
Trappc3l  8.83 
Calca calcitonin/calcitonin-related polypeptide, alpha 8.78 
Ppp1r1c protein phosphatase 1, regulatory (inhibitor) subunit 1C 8.70 
Avil advillin 8.63 
Wdr72 WD repeat domain 72 8.63 
Scn11a sodium channel, voltage-gated, type XI, alpha 8.55 
Prx thioredoxin peroxidase, pseudogene 1 8.47 
Under  
Ankrd63  -9.44 
Hpcal4 hippocalcin-like 4 -8.41 
Drd1  -8.15 
Dlx6os1  -7.94 
Foxg1  -7.92 
Gpr88 G-protein coupled receptor 88 -7.90 
Otof  -7.88 
Icam5 intercellular adhesion molecule 5, telencephalin -7.77 
Serpina9  -7.64 
Camkv CaM kinase-like vesicle-associated -7.45 
Npy neuropeptide Y -7.45 
Rasal1  -7.44 
Cecr6  -7.29 
Itpka inositol 1,4,5-trisphosphate 3-kinase A -7.24 
Vipr1  -7.20 
Zfp831  -7.16 
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Table 8. (cont.). 
Gpr6 G protein-coupled receptor 6 -7.10 
Grm5 G protein coupled receptor, family C, group 1, member E -7.07 
Emx2  -6.80 
Dlgap2   -6.74 







Table 9. Clusters of enriched functional categories (enrichment score ES > 1.7) among the genes 
differentially expressed between the trigeminal ganglia and nucleus accumbens identified using 
DAVID. 
aCategory GO Identifier and Name P-value bFDR P-value 
Cluster 1 (ES: 6)    
MF GO:0005216~ion channel activity 4.7E-14 2.1E-11 
BP GO:0006813~potassium ion transport 7.1E-06 1.2E-03 
Cluster 2 (ES: 5.3)    
KEGG mmu04080:Neuroactive ligand-receptor interaction 4.0E-12 5.5E-10 
Cluster 3 (ES: 5.1)    
BP GO:0019228~neuronal action potential 2.5E-09 1.1E-06 
MF GO:0005272~sodium channel activity 1.1E-04 7.9E-03 
Cluster 4 (ES: 3.1)    
KEGG mmu04723:Retrograde endocannabinoid signaling 2.4E-05 1.1E-03 
KEGG mmu05032:Morphine addiction 7.6E-05 2.6E-03 
MF GO:0004890~GABA-A receptor activity 3.3E-03 9.4E-02 
Cluster 5 (ES: 2.4)    
MF GO:0005262~calcium channel activity 4.4E-04 1.9E-02 
Cluster 6 (ES: 2.2)    
BP GO:0033693~neurofilament bundle assembly 7.8E-04 5.1E-02 
Cluster 7 (ES: 2.1)    
KEGG mmu05030:Cocaine addiction 8.8E-05 2.4E-03 
KEGG mmu05031:Amphetamine addiction 3.4E-03 3.1E-02 
Cluster 8 (ES: 1.8)    
BP GO:0019226~transmission of nerve impulse 3.9E-04 3.1E-02 
Cluster 9 (ES: 1.7)    
KEGG mmu04728:Dopaminergic synapse 9.3E-04 1.4E-02 
KEGG mmu04724:Glutamatergic synapse 1.7E-03 2.0E-02 
KEGG mmu04713:Circadian entrainment 3.6E-03 3.1E-02 
aBP: biological process; MF: molecular function; KEGG: KEGG pathway. 









Table 10. Transcription factors (TF) enriched (normalized enrichment score NES > 3.0) among 
genes differentially expressed between Nitroglycerin-treated and Control mice within trigeminal 
ganglia (TG, number N of target genes = 338), nucleus accumbens (NA, number N of target 
genes = 103), and across brain regions (number N of target genes = 166). 
TG  NA  Across 
TF NES Target Gene N 
 TF NES Target Gene N 
 TF NES Target Gene N 
Cebpa 5.186 18  Diablo 4.81 16  E2f1 5.128 16 
Smpx 4.447 129  Yy1 4.347 22  Barx1 4.483 18 
Smad1 4.185 36  Six6 4.268 24  Mnt 3.997 15 
Snrnp70 3.94 25  Dmrtc2 3.902 11  Hlf 3.683 21 
Sp1 3.896 160  Tcf4 3.871 10  Tead1 3.568 24 
Rfx2 3.749 103  Tbx5 3.851 8  Gata3 3.553 28 
Tfap4 3.689 83  Pura 3.837 7  Zfp706 3.51 19 
Pax6 3.626 33  Rfx2 3.74 15  Kdm4d 3.491 19 
Atf1 3.216 18  Hesx1 3.455 17  Pou5f1 3.446 40 
Tead3 3.197 15  Gata3 3.435 10  Nf1 3.411 18 
Pax3 3.191 21  Pou2f1 3.431 10  Pura 3.329 10 
    Runx3 3.315 14  Nkx2-2 3.241 14 
    Ahr 3.275 21  Jun 3.209 7 
    Mafa 3.073 10  Pou3f3 3.157 21 
        Stat1 3.15 26 
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